Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Reply to A. Ocana et al.

Cortés J, Llombart-Cussac A, Calvo E.

J Clin Oncol. 2013 Mar 20;31(9):1253-4. No abstract available.

PMID:
23616989
2.

Multidimensional challenges in clinical drug development, regulatory approval, and marketing.

Ocana A, Seruga B, Amir E.

J Clin Oncol. 2013 Mar 20;31(9):1252-3. doi: 10.1200/JCO.2012.47.5699. Epub 2013 Feb 11. No abstract available.

PMID:
23401455
3.

Making genuine progress against metastatic breast cancer.

Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA.

J Clin Oncol. 2012 Oct 1;30(28):3448-51. Epub 2012 Aug 27. Review. No abstract available.

PMID:
22927527
4.

Progress against solid tumors in danger: the metastatic breast cancer example.

Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN.

J Clin Oncol. 2012 Oct 1;30(28):3444-7. Epub 2012 Aug 27. No abstract available.

PMID:
22927522
5.

[Anti-angiogenic therapy in breast cancer].

Tanaka R, Tamura K.

Gan To Kagaku Ryoho. 2014 Feb;41(2):153-6. Japanese.

PMID:
24743193
6.

Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.

Zhou Y, Zhang Y, Yang X, Fan L, Jiang J.

Breast J. 2012 Sep;18(5):502-3. doi: 10.1111/j.1524-4741.2012.01293.x. Epub 2012 Aug 15. No abstract available.

PMID:
22891618
7.

[Anti-angiogenic therapy for breast cancer--problems and future directions].

Sawaki M, Iwata H.

Nihon Rinsho. 2012 Sep;70 Suppl 7:614-9. Japanese. No abstract available.

PMID:
23350473
8.

Avastin withdrawal symptoms.

Lynce F, Swain SM.

Expert Opin Pharmacother. 2012 Feb;13(3):293-8. doi: 10.1517/14656566.2012.652088. Epub 2012 Jan 21. No abstract available.

PMID:
22263961
9.

FDA cancels approval for bevacizumab in advanced breast cancer.

Tanne JH.

BMJ. 2011 Nov 25;343:d7684. doi: 10.1136/bmj.d7684. No abstract available.

PMID:
22121166
10.

Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer.

Lopes G, Dent R.

Oncologist. 2011;16(12):1669-71. doi: 10.1634/theoncologist.2011-0403. Epub 2011 Dec 8. No abstract available.

11.

Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Huemer F, Gampenrieder SP, Schlattau A, Greil R.

Clin Breast Cancer. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28. No abstract available.

PMID:
24246725
12.

Pushing the envelope.

[No authors listed]

Nat Biotechnol. 2011 Aug 5;29(8):669. doi: 10.1038/nbt.1956. No abstract available.

PMID:
21822220
13.

Is the battle over bevacizumab coverage looming?

Larkin C.

J Natl Compr Canc Netw. 2011 Mar;9(3):261-3. No abstract available.

PMID:
21393437
14.

Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise?

Burstein HJ.

Nat Rev Clin Oncol. 2012 Mar 13;9(4):191-2. doi: 10.1038/nrclinonc.2012.34. No abstract available.

PMID:
22411347
15.

FDA panel votes to pull Avastin in breast cancer, again.

Ratner M.

Nat Biotechnol. 2011 Aug 5;29(8):676. doi: 10.1038/nbt0811-676c. No abstract available. Erratum in: Nat Biotechnol. 2012 Feb;30(2):193.

PMID:
21822226
16.

Bevacizumab recommendation highlights difficulties.

Printz C.

Cancer. 2011 Nov 15;117(22):5025. doi: 10.1002/cncr.26642. No abstract available.

17.
18.

Avastin saga reveals debate over clinical trial endpoints.

Sharma SP.

J Natl Cancer Inst. 2012 Jun 6;104(11):800-1. doi: 10.1093/jnci/djs265. Epub 2012 Jun 6. No abstract available.

PMID:
22673590
19.

Reply to T.J. Kruser et al.

Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T.

J Clin Oncol. 2016 Apr 10;34(11):1282-3. doi: 10.1200/JCO.2015.65.2438. Epub 2016 Feb 16. No abstract available.

PMID:
26884575
20.

Information for patients. HER2+ early breast cancer: understanding adjuvant treatment.

Helwick C.

Oncology (Williston Park). 2009 Oct;23(11 Suppl Nurse Ed):8a-8b. English, Spanish. No abstract available.

PMID:
19856601

Supplemental Content

Support Center